Noxafil Powder, For Suspension
NDC Package 0085-2224-02
Package Information
Noxafil (posaconazole) powders is noxafil is indicated for the treatment of invasive aspergillosis as follows:Noxafil injection: adults and pediatric patients 2 years of age and older who weigh 10 kg or greaterNoxafil delayed-release tablets: adults and pediatric patients 2 years of age and older who weigh greater than 40 kgNoxafil PowderMix for delayed-release oral suspension: pediatric patients 2 years of age and older who weigh 10 to 40 kg. This formulation utilizes a powder, for suspension delivery system. Marketed by Merck Sharp & Dohme Llc, this product is identified by NDC 0085-2224 and is authorized under FDA application NDA214770.
Identification & Billing
- RxCUI: 1482908 - posaconazole 100 MG Delayed Release Oral Tablet
- RxCUI: 1482912 - Noxafil 100 MG Delayed Release Oral Tablet
- RxCUI: 1482912 - posaconazole 100 MG Delayed Release Oral Tablet [Noxafil]
- RxCUI: 1492043 - posaconazole 300 MG in 16.7 ML Injection
- RxCUI: 1492043 - 16.7 ML posaconazole 18 MG/ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0085 - Merck Sharp & Dohme Llc
- 0085-2224 - Noxafil
- 0085-2224-02 - 8 PACKET in 1 CARTON / 1 POWDER, FOR SUSPENSION in 1 PACKET (0085-2224-01)
- 0085-2224 - Noxafil
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0085-2224-02 identifies a specific commercial package of 8 packet in 1 carton / 1 powder, for suspension in 1 packet (0085-2224-01) of Noxafil, a human prescription drug labeled by Merck Sharp & Dohme Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 8 billable units per package. This powder, for suspension is formulated for oral use and contains posaconazole as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Merck Sharp & Dohme Llc on June 08, 2021. The current certification is valid through December 31, 2027.
How is this Merck Sharp & Dohme Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00085222402. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 8 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.